service biology, analytical, toxicology,
pharmaceutical development and process development services; and research
manufacturing, focusing on manufacturing of advanced intermediates and
active pharmaceutical ingredients for R&D use. In 2007, its 80 customers
included nine of the world's top ten pharmaceutical companies by revenue.
For more information, please visit:
http://www.wuxipharmatech.com .
For more information, please contact:
Sherry Shao
Tel: +86-21-5046-4002
Email: pr@pharmatechs.com
'/>"/>SOURCE WuXi PharmaTech Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 20072.
WuXi PharmaTech Announces Second Quarter 2007 Results3.
WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia4.
WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China5.
Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech6.
Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology7.
WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO8.
WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.9.
DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)10.
Aflac Honored with Corporate Citizenship Award11.
Dr. Dinesh Verma to be honored with Presidents Leadership Award at Edwin A. Stevens Society Gala